|
- Regeneron | Pushing the Bounds of Science
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines Join our team and explore clinical trials
- Regeneron Pharmaceuticals - Wikipedia
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation
- Investor Relations | Regeneron Pharmaceuticals Inc.
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases Learn more about Regeneron Download our corporate fact sheet
- PUSH THE BOUNDS OF SCIENCE - Regeneron
Regeneron is a leading science and technology company dedicated to inventing, developing and commercializing life-transforming treatments for serious diseases
- Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin . . .
Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in
- FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin . . .
The U S Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc REGN and Sanofi SA’s SNY Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a
- Regeneron declines to make higher bid for 23andMe after Wojcickis $305 . . .
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday
- About Regeneron | Our Company
Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases
|
|
|